Chunmou Li*1, Xiaomin Peng*1, Chuchu Feng*1, Xilin Xiong*, Jianxin Li†, Ning Liao‡, Zhen Yang§, Aiguo Liu¶, Pingping Wu*, Xuehong Liang†, Yunyan He‡, Xin Tian§, Yunbi Lin§, Songmi Wang¶, Yang Li*
Oncology Research, Vol.28, No.7-8, pp. 791-800, 2020, DOI:10.3727/096504021X16184815905096
Abstract This nonrandomized, multicenter cohort, open-label clinical trial evaluated the efficacy and safety of combined
chemotherapy with arsenic trioxide (ATO) in children with stage 4/M neuroblastoma (NB). We enrolled patients
who were newly diagnosed with NB and assessed as stage 4/M and received either traditional chemotherapy
or ATO combined with chemotherapy according to their own wishes. Twenty-two patients were enrolled in
the trial group (ATO combined with chemotherapy), and 13 patients were enrolled in the control group (traditional chemotherapy). Objective response rate (ORR) at 4 weeks after completing induction chemotherapy was
defined as the main outcome, and adverse events were monitored… More >
Login
Register
